Abstract Number: 1189 • 2012 ACR/ARHP Annual Meeting
Stromal Cell Markers in the Synovial Tissue of Patients with Early Arthritis and Preclinical Rheumatoid Arthritis
Background/Purpose: Stromal cells in synovial tissue (ST) of patients with arthritis may have an important role in the initiation and persistence of the inflammatory infiltrate.…Abstract Number: 1190 • 2012 ACR/ARHP Annual Meeting
Fine Specificity of Anti-Citrullinated Peptide Antibodies Discloses a Heterogeneous Antibody Population in Rheumatoid Arthritis (RA)
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are highly specific for the diagnosis of patients with RA. However, the predominant B cell epitopes have not yet been…Abstract Number: 1191 • 2012 ACR/ARHP Annual Meeting
Nicotinamide Adenine Dinucleotide Phosphate Oxidase Mediated Angiogenesis and Inflammation in the Arthritic Joint
Background/Purpose: To examine the role of Nicotinamide Adenine Dinucleotide Phosphate Oxidase (NADPH oxidase)-derived Reactive Oxygen Species (ROS) and NADPH oxidase-dependent redox signaling events in regulating…Abstract Number: 1192 • 2012 ACR/ARHP Annual Meeting
IL-21 Regulates B Cell Proliferation and Differentiation in Rheumatoid Arthritis
Background/Purpose: Interleukin (IL)-21 is a member of type I cytokine family. Recent studies have indicated that IL-21 is an important regulator for human B cell…Abstract Number: 1193 • 2012 ACR/ARHP Annual Meeting
Podoplanin Expression in Rheumatoid Stroma Correlates with Lymphoid Neogenesis and Is Downregulated by Anti-TNF-α Therapy
Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts (SF) expand and undergo phenotypic changes that contribute to chronic inflammation and joint destruction. Podoplanin (Pdp) is a…Abstract Number: 1194 • 2012 ACR/ARHP Annual Meeting
Prevalence of Anti-Peptidylarginine Deiminase Type 4 Antibodies in Rheumatoid Arthritis and Unaffected First-Degree Relatives in Indigenous North American Populations
Background/Purpose: Antibodies directed against peptidylarginine deiminase type 4 (PAD-4) are present in a subset of patients with rheumatoid arthritis (RA) and are associated with more…Abstract Number: 1195 • 2012 ACR/ARHP Annual Meeting
Identification of Follicular Helper T Cells As a Novel Cell Population Potentially Involved in the Pathogenesis of Rheumatoid Arthritis
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovium, causing progressive joint destruction and reduction in quality of life…Abstract Number: 1156 • 2012 ACR/ARHP Annual Meeting
Effectivity of Methotrexate in Therapy of Juvenile Idiopathic Enthesitis-Related Arthritis
Background/Purpose: Juvenile idiopathic enthesitis related arthritis (enthJIA) represents 5 to 10% of children with JIA. Most patients present with peripheral arthritis and enthesitis. Methotrexate was…Abstract Number: 1157 • 2012 ACR/ARHP Annual Meeting
The Phenotypic Characterization of Juvenile Idiopathic Arthritis in African American Children
Background/Purpose: JIA, a common childhood arthropathy, with an estimated prevalence of 1 in 1000 in children under the age of 16, affects children of all…Abstract Number: 1158 • 2012 ACR/ARHP Annual Meeting
Development of Cut-off Values for High Disease Activity in Juvenile Idiopathic Arthritis Based On the Juvenile Arthritis Disease Activity Score
Background/Purpose: In the last decade, there have been major advances in the management of juvenile idiopathic arthritis (JIA), including the shift towards early aggressive interventions…Abstract Number: 1159 • 2012 ACR/ARHP Annual Meeting
Reasons and Predictors of Methotrexate Discontinuation in Children with JIA: Results From the Childhood Arthritis Prospective Study (CAPS)
Background/Purpose: Methotrexate (MTX) is the DMARD of first choice in patients with juvenile idiopathic arthritis (JIA). However, limited data is available on MTX survival, including…Abstract Number: 1160 • 2012 ACR/ARHP Annual Meeting
Assessment of Subclinical Synovitis by Power Doppler Ultrasonography in Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood, leading to physical disability and poor quality of life. Advances in…Abstract Number: 1161 • 2012 ACR/ARHP Annual Meeting
Current Evidence of Anti-TNFα Treatment Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta-Analysis Approach Comparing the Different Drugs
Background/Purpose: To summarize evidence regarding the effectiveness of anti-TNFα treatments in childhood autoimmune chronic uveitis (ACU), non responder and/or failure to previous DMARD course.Methods: A…Abstract Number: 1162 • 2012 ACR/ARHP Annual Meeting
Patients with Juvenile Idiopathic Arthritis From a Low Socio-Economic Background Perceive Their Disease Activity and Physical Limitations Higher Than Patients from a High Socio-Economic Background
Background/Purpose: It has been suggested that socio-economic status (SES) may be associated with delayed to access to rheumatology care and with worse disease severity…Abstract Number: 1163 • 2012 ACR/ARHP Annual Meeting
Risk Factors for Radiologic Progression in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents
Background/Purpose: Progression of joint damage is sometimes observed in JIA patients during the biologic therapy. However, it is difficult to evaluate the radiographic progression by…
ACR Meeting Abstracts